Y-mAbs(YMAB) ZACKS·2025-02-25 16:00Company Overview - Y-mAbs Therapeutics, Inc. (YMAB) is expected to report a year-over-year decline in earnings despite higher revenues for the quarter ended December 2024, with a consensus EPS estimate of a loss of 27.2 million, which represents a 16.4% increase compared to the same quarter last year [3] Earnings Expectations - The earnings report is scheduled for release on March 4, 2025, and could lead to stock price movements depending on whether the actual results exceed or fall short of expectations [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] Earnings Surprise Prediction - The Most Accurate Estimate for Y-mAbs Therapeutics is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +31.65%, suggesting a bullish outlook from analysts [10] - The company currently holds a Zacks Rank of 3 (Hold), indicating a moderate expectation of beating the consensus EPS estimate [11] Historical Performance - In the last reported quarter, Y-mAbs Therapeutics was expected to post a loss of 0.16, resulting in a surprise of -14.29% [12] - Over the past four quarters, the company has only beaten consensus EPS estimates once [13] Industry Context - In the broader context of the Zacks Medical - Biomedical and Genetics industry, Apellis Pharmaceuticals, Inc. (APLS) is also expected to report a loss of $0.39 per share for the same quarter, reflecting a year-over-year change of +46.6% [17] - Apellis Pharmaceuticals has an Earnings ESP of -44.73% and a Zacks Rank of 3, making it challenging to predict a beat on the consensus EPS estimate [18]